Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the interest coverage ratio high or low?
The interest coverage ratio of -458.00x is 11% above its 1-year average of -517.23x, near the high end of its 1-year range (-632.00x–-417.81x).
As of the fiscal period ended Wednesday, March 31, 2010. 11.45% above its 12-month average of -517.23x.
Reported quarterly interest coverage; no daily interpolation. Q1 FY2010 (2010-03-31): -458.00x.
INTEREST COVERAGE RATIO
-458.00x
INTEREST COVERAGE RATIO AVG TTM
-517.23x
INTEREST COVERAGE RATIO AVG 3Y
N/A
INTEREST COVERAGE RATIO AVG 5Y
N/A
INTEREST COVERAGE RATIO AVG 10Y
N/A
INTEREST COVERAGE RATIO AVG 15Y
N/A
INTEREST COVERAGE RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+11.45%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-4.21x
median of 326 covered companies
CURRENT VS SECTOR MEDIAN
-10778.86%
vs the sector median at left
Acadia Pharmaceuticals Inc.
Market Cap
$3.44B
Interest Coverage Ratio
-458.00x
TTM Avg
-517.23x
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.58B
Interest Coverage Ratio
-2.80x
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.62B
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.25B
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.16B
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.15B
Interest Coverage Ratio
-1.01x
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.09B
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | INTEREST COVERAGE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Acadia Pharmaceuticals Inc. (ACAD) | $3.44B | -458.00x | -517.23x | N/A | N/A |
| iRhythm Technologies, Inc. (IRTC)vs › | $3.58B | -2.80x | N/A | N/A | N/A |
| Celcuity Inc. (CELC)vs › | $3.59B | -10.04x | N/A | N/A | N/A |
| CareDx, Inc (CDNA)vs › | $3.61B | N/A | 0.59x | 0.59x | 0.59x |
| IDEAYA Biosciences, Inc. (IDYA)vs › | $3.62B | N/A | N/A | N/A | N/A |
| Enliven Therapeutics, Inc. (ELVN)vs › | $3.25B | N/A | N/A | N/A | N/A |
| Denali Therapeutics Inc. (DNLI)vs › | $3.16B | N/A | N/A | N/A | N/A |
| Arcutis Biotherapeutics, Inc. (ARQT)vs › | $3.15B | -1.01x | N/A | N/A | N/A |
| Amylyx Pharmaceuticals, Inc. (AMLX)vs › | $3.09B | N/A | N/A | N/A | N/A |
| Dyne Therapeutics, Inc. (DYN)vs › | $2.88B | -75.61x | 0.12x | 0.12x | 0.12x |
Interest Coverage
-458.0x
Debt/Equity
0.06
Current Ratio
3.39
Formula: Interest Coverage = EBIT / Interest Expense
Reference ranges:
Note: Interest coverage should be compared with historical interest expense, operating income, and industry capital structure.
Interest Coverage = EBIT / Interest Expense
The interest coverage ratio measures operating earnings relative to interest expense.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | INTEREST COVERAGE RATIO |
|---|---|
| 2010-03-31 | -458.00x |
| 2009-12-31 | -544.13x |
| 2009-09-30 | -417.81x |
| 2009-06-30 | -534.21x |
| 2009-03-31 | -632.00x |
